¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Insulin"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • insulinemia
    Àν¶¸°Ç÷Áõ
  • insulinization
    Àν¶¸°¿ä¹ý
  • insulinoma
    Àν¶¸°Á¾
  • insulinopenic
    Àν¶¸°°áÇÌ-
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • insulin tolerance test
    Àν¶¸°³»¼º½ÃÇè.
  • insulin tolerance test
    Àν¶¸°³»¼º½ÃÇè
  • Insulin-like growth factors
    Àν¶¸°¾ç(å×)¼ºÀå(à÷íþ)È£¸£¸ó
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • insulin resistance
    Àν¶¸°ÀúÇ×¼º.
  • insulin secreting islet cell tumor
    Àν¶¸° ºÐºñ¼º µµ¼¼Æ÷Á¾¾ç.
  • insulin sensitivity
    Àν¶¸°°¨(¼ö)¼º.
  • insulin sensitivity index
    Àν¶¸°°¨¼ºÁö¼ö.
  • insulin sensitivity test
    Àν¶¸°°¨¼º½ÃÇè.
  • insulin shock
    Àν¶¸°¼ï.
  • insulin shock therapy
    Àν¶¸°¼ï¿ä¹ý.
  • insulin shock treatment
    Àν¶¸°Ãæ°ÝÄ¡·á.
  • insulin test
    Àν¶¸°½ÃÇè.
  • insulin therapy
    Àν¶¸°Ä¡·á, Àν¶¸°¿ä¹ý.
  • insulin tolerance
    Àν¶¸°³»¼º.
  • insulin tolerance test
    Àν¶¸°³»¼º½ÃÇè
  • insulin tolerance test
    Àν¶¸°³»¼º½ÃÇè.
  • insulin treatment
    Àν¶¸°Ä¡·á.
  • insulin unit
    Àν¶¸°´ÜÀ§.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lente insulin
    ·»Å×Àν¶¸°.
  • long acting insulin
    Áö¼Ó¼º Àν¶¸°.
  • monocomponent insulin
    ´Ü(ÀÏ)¼ººÐÀν¶¸°.
  • non-suppressible insulin-like activity
    ºñ¾ïÁ¦Àν¶¸°¾ç Ȱ¼º
  • oral insulin substitute
    °æ±¸(Àû) ´ë¿ë(ÌèÏ¢îÜÓÛéÄ)Àν¶¸°, °æ±¸(Àû) Àν¶¸° ´ë¿ë¾à(¡­ÓÛéÄå·).
  • oral insulin substitute
    °æ±¸(Àû) ´ë¿ë(ÌèÏ¢(îÜ) ÓÛéÄ)Àν¶¸°, °æ±¸(Àû) Àν¶¸° ´ë¿ë¾à(¡­ÓÛéÄå·).
  • protamin insulin(e)
    ÇÁ·ÎŸ¹ÎÀν¶¸°.
  • protamin(e) insulin
    ÇÁ·ÎŸ¹ÎÀν¶¸°.
  • protamin(e) zinc insulin
    ÇÁ·ÎŸ¹Î¾Æ¿¬ Àν¶¸°.
  • protamin(e) zinc insulin
    ÇÁ·ÎŸ¹Î¾Æ¿¬ Àν¶¸°.
  • purified insulin
    ¼ø¼öÀν¶¸°.
  • short acting insulin
    ¼ÓÈ¿¼º Àν¶¸°.
  • suppressive insulin
    ¾ïÁ¦Çü(åäð¤úþ)Àν¶¸°.
  • ultralente insulin
    ÃÊÁö¿¬¼º Àν¶¸°.
  • zinc insulin crystals
    ¾Æ¿¬Àν¶¸°°áÁ¤(¡­Ì¿ïÜ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CSII Continuous Subcutaneous Insulin Infusion
CZI Crystalline Zinc Insulin
GI   1) Gastro-Intestinal; À§ÀåÀÇ
  2) Globin Insulin
  3) Granuloma I...
IDDM Insulin Dependent Diabetes Mellitus
  = Type I DM
IGF Insulin-like Growth Factor
  = Somatomedin
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
IGF I C/insulin-like growth factor I
CSII Continuous Subcutaneous Insulin Infusion
FIRI Fasting insulin resistance index
FPI Fasting plasma insulin
FPIR First-phase insulin response
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
insulin pump A device that delivers a continuous supply of insulin into the body. The insulin flows from the pump through a plastic tube that is connected to a needle inserted into the body and taped in place. Insulin is delivered at two rates: a low, steady rate (called the basal rate) for continuous day-long coverage, and extra boosts of insulin (called bolus doses) to cover meals or when extra insulin is needed. The pump runs on batteries and can be worn clipped to a belt or carried in a pocket. It is used by people with insulin-dependent diabetes.
(09 Oct 1997)
insulin reaction A sudden uncontrolled decline in the blood sugar due to effects of insulin.
(27 Sep 1997)
insulin receptor Areas on the outer part of a cell that allow the cell to join or bind with insulin that is in the blood. When the cell and insulin bind together, the cell can take glucose (sugar) from the blood and use it for energy.
(09 Oct 1997)
insulin receptor protein-tyrosine kinase <enzyme> A catalytic protein-tyrosine kinase domain found on the cytoplasmic beta-portion of the insulin receptor.
Registry number: EC 2.7.1.-
(12 Dec 1998)
insulin receptor substrate-1 protein <chemical> Amino acid sequence given in first source; a 180 kD protein that contains multiple phosphorylated tyrosine residues after insulin stimulation; human and rat forms (hirs-1 and irs-1) are homologous
Synonym: insulin receptor substrate-1-like protein, irs-1 protein, irs-1 gene product, hirs-1 protein, hirs-1 gene product, insulin receptor substrate 1, insulin receptor substrate-1
(05 Dec 1998)
insulin resistance Many people with noninsulin-dependent diabetes produce enough insulin, but their bodies do not respond to the action of insulin. This may happen because the person is overweight and has too many fat cells, which do not respond well to insulin. Also, as people age, their body cells lose some of the ability to respond to insulin. Insulin resistance is also linked to high blood pressure and high levels of fat in the blood. Another kind of insulin resistance may happen in some people who take insulin injections. They may have to take very high doses of insulin every day (200 units or more) to bring their blood glucose (sugar) down to the normal range.
(09 Oct 1997)
insulin shock A severe condition that occurs when the level of blood glucose (sugar) drops quickly. The signs are shaking, sweating, dizziness, double vision, convulsions, and collapse. Insulin shock may occur when an insulin reaction is not treated quickly enough.
See: hypoglycaemia.
(09 Oct 1997)
insulin shock treatment Formerly used treatment for serious mental disorders in which the patient was given insulin to induce a seizure; supplanted by electroshock therapy.
(05 Mar 2000)
insulin unit The activity contained in 1/22 mg of the international standard of zinc-insulin crystals.
(05 Mar 2000)
insulin zinc suspension A sterile buffered suspension with zinc chloride, containing 40 or 80 units per ml; the solid phase of the suspension consists of a mixture of 7 parts of crystalline insulin and 3 parts of amorphous insulin.
Synonym: lente insulin.
(05 Mar 2000)
insulin, isophane <chemical> An intermediate-acting insulin with an approximate time of onset of 2 hours and duration of action of 24 hours, consisting of bovine or pork insulin reacted with zinc chloride and protamine to form a protein complex with a ratio of free and bound insulin, providing action intermediate between regular insulin and protamine zinc insulin.
Pharmacological action: hypoglycaemic agents.
Chemical name: Insulin Isophane
(12 Dec 1998)
insulin, lente <chemical> Sterile suspension, in a buffered water medium, of insulin modified by the addition of zinc chloride in a manner such that the solid phase of the suspension conisists of a mixture of crystals and amorphous material in a ratio of approximately 7:3.
Pharmacological action: hypoglycaemic agents.
Chemical name: Insulin zinc
(12 Dec 1998)
insulin, protamine zinc <chemical> A long-acting insulin with an approximate time of onset of 7 hours and duration of action 36 hours, consisting of bovine or pork insulin reacted with zinc chloride and protamine to form a protein complex from which insulin is slowly released.
Pharmacological action: hypoglycaemic agents.
Chemical name: Insulin protamine zinc
(12 Dec 1998)
insulin-antagonizing factor A principle in extracts of the anterior lobe of the hypophysis that raises the blood sugar and antagonises the action of insulin; purified pituitary growth hormone produces an identical effect.
Synonym: insulin-antagonizing factor.
(05 Mar 2000)
insulin-dependent diabetes mellitus A chronic condition in which the pancreas makes little or no insulin because the beta cells have been destroyed. The body is then not able to use the glucose (blood sugar) for energy. IDDM usually comes on abruptly, although the damage to the beta cells may begin much earlier. The signs of IDDM are a great thirst, hunger, a need to urinate often, and loss of weight. To treat the disease, the person must inject insulin, follow a diet plan, exercise daily, and test blood glucose several times a day. IDDM usually occurs in children and adults who are under age 30. This type of diabetes used to be known as juvenile diabetes, juvenile-onset diabetes, and ketosis-prone diabetes.
(09 Oct 1997)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
non-insulin-dependent diabetes mellitus <disease> An often mild form of diabetes mellitus of gradual onset, usually in obese individuals over age 35; absolute plasma insulin levels are normal to high, but relatively low in relation to plasma glucose levels; ketoacidosis is rare, but hyperosmolar coma can occur; responds well to dietary regulation and/or oral hypoglycaemic agents, but diabetic complications and degenerative changes can develop.
(05 Mar 2000)
nonsuppressible insulin-like activity A blood protein (nsila) which mimics the biological activity of insulin in serum, but is not suppressed by insulin antibodies. During acid-ethanol extraction of cohn fraction III, 10% of the activity is found in the supernatant (nsila-s) and the remaining activity in the precipitate (nsila-p). The latter is a large molecular compound, much less stable than the soluble fraction. Nsila-s is a more potent growth factor than insulin and exhibits sulfation activity.
(12 Dec 1998)
NPH insulin isophane insulin
diabetes mellitus, insulin-dependent Diabetes mellitus characterised by insulin deficiency, sudden onset, severe hyperglycaemia, rapid progression to ketoacidosis, and death unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
(12 Dec 1998)
diabetes mellitus, non-insulin-dependent Diabetes characterised by the ability to survive without ketoacidosis in the absence of insulin therapy. It is usually of slow onset and patients exhibit a tendency to obesity.
(12 Dec 1998)
extended insulin zinc suspension A long-acting insulin suspension, obtained from beef, with an approximate time of onset of 7 hours and a duration of action of 36 hours.
Synonym: crystalline insulin zinc suspension.
(05 Mar 2000)
ultralente insulin A form of zinc precipitated insulin in suspension in which the particle size is large, and thus release into the bloodstream after subcutaneous injection is slow; it can be mixed with other insulins having different particle sizes to achieve different durations of activity. Can be derived from porcine, bovine, or genetically engineered human type.
(05 Mar 2000)
lente insulin A sterile buffered suspension with zinc chloride, containing 40 or 80 units per ml; the solid phase of the suspension consists of a mixture of 7 parts of crystalline insulin and 3 parts of amorphous insulin.
Synonym: lente insulin.
(05 Mar 2000)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 5 ÆäÀÌÁö: 2
  • Insulin Resistance - »õâ Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. It can be caused by the presence of INSULIN ANTIBODIES or the abnormalities in insulin receptors (RECEPTOR, INSULIN) on target cell surfaces. It is often associated with OBESITY; DIABETIC KETOACIDOSIS; INFECTION; and certain rare conditions. (from Stedman, 25th ed)
    Synonyms : Resistance, Insulin
  • Insulin, Isophane - »õâ A modified form of insulin that contains protamine and zinc. Isophane insulin is an intermediate-acting INSULIN with time of onset of 2 hours and duration of 24 hours.
    Synonyms : Insulin, Isophane, Beef-Pork, Insulin, Isophane, Pork, Insulin, NPH, Insulin, NPH, Beef, Insulin, NPH, Beef-Pork, Insulin, NPH, Human, Insulin, NPH, Pork, Isophane Insulin, Beef, Isophane Insulin, Beef-Pork, Isophane Insulin, Human, Isophane Insulin, Pork
  • Insulin, Long-Acting - »õâ Insulin formulation containing substance which delays or retards time period of the absorption of insulin.
    Synonyms : Insulin Novo Monotard, Insulin, Lente, Insulin, Lente, Monocomponent, Insulin, Monotard, Insulin, Protamine Zinc, Insulin, Protamine Zinc, Beef-Pork, Insulin, Semilente, Long-Acting Insulin, Mixtard, Protophan, Ultralente Insulin, Insulin, Long Acting
  • Insulin-Like Growth Factor Binding Protein 1 - »õâ One of the six homologous proteins that specifically bind insulin-like growth factors (SOMATOMEDINS) and modulate their mitogenic and metabolic actions. The function of this protein is not completely defined. However, several studies demonstrate that it inhibits IGF binding to cell surface receptors and thereby inhibits IGF-mediated mitogenic and cell metabolic actions. (Proc Soc Exp Biol Med 1993;204(1):4-29)
    Synonyms : IGF Binding Protein 1, Insulin Like Growth Factor Binding Protein 1
  • Insulin-Like Growth Factor Binding Protein 2 - »õâ One of the six homologous soluble proteins that bind insulin-like growth factors (SOMATOMEDINS) and modulate their mitogenic and metabolic actions at the cellular level.
    Synonyms : IGF Binding Protein 2, IGFBP 2, Insulin Like Growth Factor Binding Protein 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 5 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 5 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
ÈÞ¸¶·Î±×¹Í½ºÁÖ25ÁÖ100´ÜÀ§/ml - »õâ
Çѱ¹¸±¸®
E00510421 insulin lispro(insulin lispro protamine/insulin lispro 75%/25%)
Àü¹®ÀǾàǰ | »èÁ¦
ÈÞ¸¶·Î±×¹Í½º25ÆæÁÖ100´ÜÀ§/ml - »õâ
Çѱ¹¸±¸®
E00510451 insulin lispro(insulin lispro protamine/insulin lispro 75%/25%)
Àü¹®ÀǾàǰ | ±Þ¿©
¾ÖÇǵå¶óÁÖ¿ÉÆ¼¼Â - »õâ
»ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ
E06400331 Insulin glulisine
Àü¹®ÀǾàǰ | ±Þ¿©
¾ÖÇǵå¶óÁÖ¹ÙÀÌ¾Ë - »õâ
»ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ
E06400311 Insulin glulisine
Àü¹®ÀǾàǰ | ±Þ¿©
·¹¹ö¹Ì¾îÇ÷º½ºÆæÁÖ100´ÜÀ§/ml - »õâ
³ëº¸³ëµð½ºÅ©
E08720361 Insulin detemir
Àü¹®ÀǾàǰ | ±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 10 ÆäÀÌÁö: 2
  • Insulin Isophane Pork Pure SubQ - »õâ
  • Insulin L Pork Purified SubQ - »õâ
  • Insulin Lente Beef SubQ - »õâ
  • Insulin Lisp & Lisp Prot (Hum) SubQ - »õâ
  • Insulin Lispro (Human) SubQ - »õâ
  • Insulin Needles (Disposable) Misc - »õâ
  • Insulin NPH Human Recomb SubQ - »õâ
  • Insulin NPH Human Semi-Syn SubQ - »õâ
  • Insulin NPH InnoLet SubQ - »õâ
  • Insulin NPH, Beef-Pork SubQ - »õâ
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
insulin-dependent diabetes mellitus Diabetes mellitus is a medical disorder characterized by varying or persistent hyperglycemia (elevated blood sugar levels), especially after eating. All types of diabetes mellitus share similar symptoms and complications at advanced stages. Hyperglycemia itself can lead to dehydration and ketoacidosis. ...
Ãâó: en.wikipedia.org/wiki/Insulin-Dependent_Diabetes_M...
insulin A hormone made by the islet cells of the pancreas. Insulin controls the amount of sugar in the blood by moving it into the cells, where it can be used by the body for energy.
Ãâó: www.stjude.org/glossary
insulin A hormone produced by the pancreas which is necessary for glucose to be able to enter the cells of the body and be used for energy.
Ãâó: www.peteducation.com/dict_alpha_listing.cfm
insulinoma Insulin-producing tumor of the pancreas; the increased production and blood level of insulin resulting from these tumors can cause low blood sugar (hypoglycemia).
Ãâó: www.peteducation.com/dict_alpha_listing.cfm
insulin A hormone that controls blood sugar levels. Diabetes is caused by a lack of insulin or resistance to insulin.
Ãâó: www.amfar.org/cgi-bin/iowa/bridge.html
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á